OL-033 Etambutol-mediated changes in rat liver cytochrome P-450 isoforms expression and DNA-fragmentation processes  by Anisimova, S. et al.
S26 Abstracts, 5th DICID
source for most antibiotics on the market today, including
the ﬁrst-line and salvage TB regimens, including rifampin,
streptomycin, amikacin and etc. A set of Microbial Natural
Product Library (MNPL) containing secondary metabolites
from a unique collection of actinomycetes and fungal
strains from un- or under-explored ecological niches in China
has been constructed. A pilot screen for potential anti-TB
compounds was conducted with a selection of 5,000 extracts
samples from this MNPL, utilizing a GFP labeled M. bovis
BCG based HTS model (Z’-factor 0.8, CV < 15%, throughput
60,000 wells/day). 80 out of the 5,000 extracts showed
>90% inhibition against logarithmically growing BCG were
further evaluated on M. tb H37Rv strains at Broad Institute,
as a dilution series ranging from 1× to 1/128×. The
results showed that 46 extracts demonstrated anti-H37Rv
activity, with 8 showing activity at 1/16×, and 1 showing
activity at 1/128×. The following large scale fermentation
and bioactivity guided compound isolation work lead to
the discovery of diversiﬁed class of anti-TB compounds,
including actinomycins (MIC 1 4 ug/ml), quinomycins (MIC
0.5 ug/ml), nanaomycins (MIC 8 ug/ml), cyclopeptides (MIC
2 8 ug/ml), anthraquinones (MIC 4 8 ug/ml), oligomycins,
part of which were new compounds (not listed).
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Objectives: Etambutol is one of ﬁrst-line antitubercular
drugs in current therapeutic regimens. Its main
disadvantage is wide spectrum of adverse effects which can
lead to therapeutic failure. The aim of present study was to
investigate etambutol effects on rat liver cytochrome P-450
isoforms expression and DNA-fragmentation processes.
Methods: Wistar albino male rats (160 200 g b.w.) were
divided into two groups: I received etambutol per os at a
dose of 155mg/kg b.w./day, II control. After 60 days of the
experiment, rats were sacriﬁced via cervical dislocation.
Expression of rat liver CYP2E1, CYP3A2 and CYP2C23
were studied by RT-PCR methods. DNA fragmentation was
investigated electrophoretically.
Results: Our data demonstrated etambutol-mediated
quantitative and qualitative changes in male rat DNA
fragmentation and expression of CYP2E1, CYP3A2 and
CYP2C23 in comparison with control. CYP2E1 and CYP3A2
expression increasing was accompanied with CYP2C23
expression inhibition. DNA fragmentation processes were
also greatly intensiﬁed at etambutol treatment. Its
introduction caused appearance of new fractions with
longer DNA-fragments (above 1000 b.p., 1000 800 b.p. and
800 600 b.p.). Among shorter DNA-fragments main fraction
contained chains with 20 30 b.p.
Conclusion: Thus etambutol treatment caused adverse
effects in organisms on the level of cytochrome P-450
isoforms expression and DNA-fragmentation processes.
Extensive investigation of etambutol and cytochrome P-450
system interactions allowed to prevent or correct this
antitubercular agent adverse effects.
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Background: This study examines the differences between
culture positive extrapulmonary and pulmonary tuberculosis
(TB) patients. It correlates these ﬁndings with the current
understanding of extrapulmonary TB. It looks at how these
factors affect mortality at six months and at the role of
underlying diseases in drug resistance.
Method: This is a two year retrospective study comparing
115 extrapulmonary TB patients with 115 pulmonary TB
patients.
Results: Extrapulmonary patients were younger than
pulmonary patients with a median age of 53 years versus
73 years (p < 0.001). They presented more commonly
with lymphadenopathy (p < 0.001). More extrapulmonary
patients had chronic renal failure (p < 0.002) and Human
Immunodeﬁciency Virus (HIV) infection (p = 0.005). They had
a higher median erythrocyte sedimentation rate (61mm/h
vs. 48mm/h, p = 0.017), and lactate dehydrogenase level
(309U/L vs. 197U/L, p = 0.006). They had a lower median
hemoglobin (10.7 g/dL vs. 11.7 g/dL, p = 0.002), white
blood cell count (7.4×109/L vs. 8.5×109/L, p = 0.039), and
lymphocyte count (0.9×109/L vs. 1.1×109/L, p = 0.051).
There was no difference in mortality between
extrapulmonary and pulmonary groups. Multivariate
analysis identiﬁed age >60 years (Odds Ratio [OR] 2.4,
95% Conﬁdence interval [95%CI] 0.98 5.77, p = 0.054),
presentation with decreased general condition (OR 3.5,
95%CI 1.46 8.34, p = 0.005), hypertension (OR 2.7, 95%CI
1.16 6.38, p = 0.021), radiological old TB (OR 2.6, 95%CI
1.25 5.52, p = 0.014), and pleural effusion (OR 3.2, 95%CI
1.45 7.03, p = 0.004) as independent risk factors for
mortality.
9.1% of all cases had culture evidence of drug resistance. HIV
infection (p = 0.001) and intravenous drug usage (p = 0.001)
were the two risk factors identiﬁed.
Conclusion: There are important differences in
demographics, clinical presentation and risk factors for
extrapulmonary compared with pulmonary TB. Mortality is
related to age and co-morbidity.
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Objectives: Tuberculosis, MTB or TB is the seventh leading
frequent cause of death worldwide among infectious
diseases. It is important to evaluate the current burden
of disease, to know how this has been changing over time.
Method: Review of current literature.
Result: According to the WHO, an estimated about 9.2
million (139/100,000 population) new cases of TB occurred
in 2006. Of these cases, 4.1 million (62/100,000 population)
were new smear positive cases. There were 14.4 million
(219/100,000 population) prevalent cases. There are 22
high-burden countries, but the majority of patients with TB
live in the eight country of Asia; India, China, Indonesia,
Bangladesh, Pakistan, Philippines, Vietnam and Afghanistan.
India is the highest TB burden country in the world
and accounts for nearly one-ﬁfth (20%) of global burden
of tuberculosis. In India, TB affects adults in the most
productive age group (15 54 years). More than 80% of TB
cases are in this group. TB kills almost 0.37 million Indian
people every year with mortality rate of about 28/100,000
population. Globally, the case detection rate by DOTS
programs increased almost linearly from 11% in 1995 to 28%
in 2000, and then accelerated to 45% in 2003. The recent
acceleration has been mostly due to rapid implementation
in India, where case detection increased from 1.7% in 1998
to 47% in 2003, and in China, where it increased from 30% in
2002 to 43% in 2003. India and China together accounted for
